Eyenovia Announces Kinetiq Co-Branded Hyperliquid Validator Partnership

Eyenovia, a pioneer in ophthalmic technologies, has announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol. This marks a significant step in Eyenovia's onchain engagement strategy, utilizing its HYPE token holdings to contribute to network stability and security. The validator is supported by infrastructure provided by Pier Two, an institutional staking services provider.

Eyenovia, Inc., a leading ophthalmic technology firm, has announced a strategic partnership with Kinetiq to introduce a co-branded Hyperliquid validator, named "Kinetiq x Hyperion." This move marks Eyenovia's entry into the blockchain infrastructure arena, leveraging its substantial acquisition of 1,040,584.5 HYPE tokens, the native currency of the Hyperliquid protocol [2].

The validator, which aims to enhance network stability and security, is supported by Pier Two, an institutional staking services provider renowned for its SOC 2 Type I and II certified operations. This collaboration allows Eyenovia to actively engage with the Hyperliquid ecosystem, moving beyond mere asset holdings to generating potential value through network participation [2].

Eyenovia's entry into the blockchain space is part of a broader strategic shift, as the company navigates financial headwinds. Despite ongoing challenges such as weak gross profit margins and accelerated cash usage, the launch of this validator node represents a shift toward a more diversified and innovation-driven business strategy [1].

The HYPE token offers utility through reduced trading fees and enhanced referral bonuses when staked, and as of June 2025, it ranks as the 12th-largest cryptocurrency by market capitalization [1]. By integrating blockchain engagement into its business model, Eyenovia provides its investors with a dual value proposition—exposure to its traditional ophthalmic business alongside blockchain-enabled returns from the Hyperliquid protocol [2].

Eyenovia's commitment to innovation is further demonstrated by its recent restructuring of its senior secured debt agreement with Avenue Capital Group, which extends the loan's maturity to July 2028 and reduces the interest rate from 12% to 8% [1]. Additionally, the company has announced a $50 million private placement to support its crypto initiatives, with plans to surpass 1 million HYPE tokens in its holdings [1].

The launch of the "Kinetiq x Hyperion" validator demonstrates Eyenovia's dedication to innovative financial strategies, presenting investors with unique opportunities to benefit from both ophthalmic technology advancements and the rapidly evolving cryptocurrency market [2].

References:
[1] https://www.cointrust.com/market-news/eyenovia-enters-blockchain-arena-with-validator-on-hyperliquid
[2] https://www.gurufocus.com/news/2944968/eyenovia-announces-cobranded-validator-with-kinetiq-eyen-stock-news